Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Sun Pharmaceutical Industries Ltd
| Quarterly Financial Results Q3 FY 2025-26
Summary : Sun Pharma reports strong Q3FY26 growth, driven by key markets and innovative medicines, despite exceptional charges.
Quarterly Report Analysis & Insights
Financial Disclosures
- Q3FY26 Consolidated R&D investment: Rs. 8,928 million (5.8% of sales).
- 9mFY26 Consolidated R&D investment: Rs. 25,783 million (5.9% of sales).
- Exceptional items (Consolidated): Q3FY26 Rs. 4,894.8 Million; 9mFY26 Rs. 13,074.8 Million.
- Exceptional tax credit (Consolidated): 9mFY26 Rs. 4,220.8 Million.
- Q3FY26 Consolidated Sales: Rs. 154,691 million, up 15.1% YoY.
- 9mFY26 Consolidated Sales: Rs. 436,604 million, up 11.3% YoY.
- India Formulations: Q3FY26 Rs. 49,986 million (32.3% of total sales), up 16.2%.
- US Formulations: Q3FY26 US$ 477 million, up 0.6%.
- Emerging Markets: Q3FY26 US$ 337 million, up 21.6%.
- Rest of World: Q3FY26 US$ 296 million, up 14.5%.
- Innovative Medicines: Q3FY26 US$ 423 million (incl. US$ 55 million milestone), up 13.2% ex-milestone.
- API: Q3FY26 Rs. 5,412 million, down 4.7%.
- National Prescription Opiate Litigation and similar putative class actions in Canada.
- Implications of New Labour Codes on employee benefits.
- Paid-up equity share capital: Rs. 2,399.3 million.
- Other equity: Rs. 719,780.9 million (Year ended 31.03.2025).
- Both standalone and consolidated financial results are presented and reviewed.
Corporate Overview
- India
- Global Emerging Markets
- Rest of World (RoW) markets
- Over 100 countries
- Manufacturing facilities across five continents
- Discontinuation of SCD-044 development work.
- Settlement agreement for End Payer Plaintiffs class.
- Implications of New Labour Codes on employee benefits.
- National Prescription Opiate Litigation and similar class actions.
- API portfolio supports formulation business and API customers.
- World's leading specialty generics company.
- Presence in Innovative Medicines, Generics, Consumer Healthcare.
- Largest pharmaceutical company in India.
- Leading generic company in US and Global Emerging Markets.
- High growth Innovative Medicines portfolio (dermatology, ophthalmology, onco-dermatology).
- Vertically integrated operations deliver high-quality medicines.
- Manufacturing facilities spread across five continents.
- Multi-cultural workforce from over 50 nations.
- Well-rounded growth across all businesses.
- Prominently led by Branded businesses in India, Emerging Markets, Global Innovative Medicines.
- Innovative product offering expanded with new launches.
- New initiatives bring differentiated therapies closer to patients.
- Physicians and consumers in over 100 countries.
- India Formulations
- US Formulations
- Emerging Markets Formulations
- Rest of World (ROW) Formulations
- Innovative Medicines
- Active Pharmaceutical Ingredients (API)
- Manufacturing facilities spread across five continents.
- Continued investment in R&D for pipeline development.
Risk Factors
- Discontinuation of SCD-044 development.
- Significant legal settlement charges.
- New Labour Codes implications.
- Decline in API segment sales.
Key Drivers
- Strong growth in India formulations.
- Innovative medicines sales increasing.
- New product launches successful.
- Healthy R&D pipeline progress.
Auditor’s Report
- Unmodified review conclusion for standalone financial results.
- Unmodified review conclusion for consolidated financial results.
Board Commentary
- Interim dividend of Rs. 11/- per equity share declared for FY 2025-26.
- Record date for dividend entitlement is February 05, 2026.
- Interim dividend to be paid on or before February 16, 2026.
- Discontinuation of development work leading to impairment.
- Significant legal settlement charges.
- Implications of new labor codes on employee benefits.
- Ongoing legal matters like Opiate Litigation.
- New Labour Codes effective November 21, 2025, impacting employee benefits.
- Settlement agreement with End Payer Plaintiffs class (Taro/SPIINC).
- National Prescription Opiate Litigation settlement.
- Discontinuation of SCD-044 development work, leading to impairment of intangible asset.
- Merger of five wholly-owned subsidiaries into the Company approved by NCLT.
Corporate Governance
- Audit Committee reviewed financial results.
Management Discussion & Analysis
Future Strategy
- Continued investment in R&D for innovative and generic pipelines.
- Expanding innovative product offerings.
- Monitoring and adapting to New Labour Codes implications.
Operational Focus Areas
- Building pipeline for various markets.
- Launching new products.
- Ensuring compliance with new labor codes.
Performance Drivers
- Well-rounded growth across all businesses.
- Strong performance in Branded businesses (India, Emerging Markets, Global Innovative Medicines).
- Successful launch of new innovative products (Unloxcyt in US, Ilumya in India).
Risk Control Measures
- Assessed implications of New Labour Codes and recognized incremental cost.
- Settlement agreements for legal issues (Taro/SPIINC, Opiate Litigation).
- Monitoring developments pertaining to New Labour Codes.
Critical Risks
- Discontinuation of development work leading to impairment.
- Significant legal settlement charges.
- Implications of new labor codes on employee benefits.
- Ongoing legal matters like Opiate Litigation.